Xiulei Mo
Associate Professor Emory University
Xiulei Mo is Assistant Professor of Pharmacology and Chemical Biology at Emory University School of Medicine, where he investigates tumor suppressor biology and develops innovative cancer therapeutics. His laboratory combines chemical biology, protein interaction technologies, and drug discovery approaches to identify new biomarkers, therapeutic targets, and mechanisms of cancer progression.
Seminars
Wednesday 27th January 2027
Panel Discussion: De-Risking Molecular Glue Development: What Does It Take to Build a Clinically and Commercially Successful Programme?
4:00 pm
- How can developers integrate proteomics, mechanistic biology, translational biomarkers, and emerging clinical data to identify safety liabilities early and improve confidence in candidate selection?
- What are the most important scientific, clinical, regulatory, and commercial risks facing molecular glue programmes today, and how should biotech leaders, investors, and drug developers assess them when making development and funding decisions?
- As more molecular glues advance toward the clinic, what frameworks are needed to evaluate off-target effects, long-term biological consequences, and programme differentiation to enable informed go/no-go, partnering, and investment decisions?
Thursday 28th January 2027
The Convergence of Genetic and Chemical Glues: Programming Protein Interaction Networks for Precision Therapeutics
11:30 am
- Introducing the concept of genetic glues—disease-associated mutations that rewire protein interaction networks—to establish a unified framework linking genetic perturbations with chemical glue pharmacology.
- Demonstrating how mutation-directed and neo-cysteine molecular glues selectively reprogram disease-specific protein interaction networks, enabling therapeutic activation of previously undruggable tumor suppressors.
- Presenting a next-generation discovery strategy that integrates cancer genetics, protein interaction network biology, and induced-proximity chemistry to expand molecular glue therapeutics beyond targeted protein degradation.
